Disease progression and outcome measures in spinobulbar muscular atrophy
- 25 October 2018
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 84 (5) , 754-765
Abstract
Objective: Spinal and bulbar muscular atrophy (SBMA) is a slowly progressive disease with weakness of bulbar and extremity muscles. There is no curative treatment for the disease, but several clinical trials have been conducted over the past years. The results from these trials have uncovered a great need to develop quantitative, reliable outcome measures. In this study, we prospectively investigated disease progression over 18 months in 29 patients with genetically confirmed SBMA, using quantitative outcome measures, including Dixon magnetic resonance imaging (MRI).Methods: We used MRI to assess changes in muscle fat content and stationary dynamometry to assess changes in muscle strength. Disease progression was also investigated with the SBMA functional rating scale, bulbar rating scale, 6‐minute walk test, and blood samples, among others.Results: Mean muscle fat content, muscle strength in knee extensors, handgrip strength, walking distance, and creatinine levels changed significantly. Mean muscle fat content increased by 2 ± 1.25%, and knee extension strength decreased from 83 ± 60 to 76 ± 56Nm, handgrip strength from 31 ± 13 to 29 ± 13kg, walking distance from 362 ± 216 to 336 ± 219m, and creatinine level from 58 ± 21 to 54 ± 20 μmol/l. Functional rating scores did not change.Interpretation: The present study demonstrates a slow and steady disease progression in SBMA. Dixon MRI detected increases in muscle fat content in all investigated muscles and is therefore a suitable candidate for an outcome measure in natural history or treatment studies in SBMA. The 6‐minute walk test and handgrip strength also seem to be reliable outcome measures for SBMA. Ann Neurol 2018;84:762–773Keywords
Funding Information
- Augustinus Fonden
- Aase and Ejnar Danielsen Foundation
This publication has 35 references indexed in Scilit:
- The metabolic and endocrine characteristics in spinal and bulbar muscular atrophyJournal of Neurology, 2018
- Long-term treatment with leuprorelin for spinal and bulbar muscular atrophy: natural history-controlled studyJournal of Neurology, Neurosurgery & Psychiatry, 2017
- MRI as outcome measure in facioscapulohumeral muscular dystrophy: 1-year follow-up of 45 patientsJournal of Neurology, 2016
- Onset Manifestations of Spinal and Bulbar Muscular Atrophy (Kennedy’s Disease)Journal of Molecular Neuroscience, 2015
- Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trialThe Lancet Neurology, 2011
- Clinical features of spinal and bulbar muscular atrophyBrain, 2009
- Spinal and bulbar muscular atrophy: a motoneuron or muscle disease?Current Opinion in Pharmacology, 2008
- Dixon techniques for water and fat imagingJournal of Magnetic Resonance Imaging, 2008
- Natural history of spinal and bulbar muscular atrophy (SBMA): a study of 223 Japanese patientsBrain, 2006
- Testosterone Reduction Prevents Phenotypic Expression in a Transgenic Mouse Model of Spinal and Bulbar Muscular AtrophyNeuron, 2002